✦ LIBER ✦

Cytologic features of mixed papillary carcinoma and chronic lymphocytic leukemia/small lymphocytic lymphoma of the thyroid gland

✍ Scribed by Michelle Reid-Nicholson; Andre Moreira; Preetha Ramalingam

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 265 KB
Volume: 36
Category: Article
ISSN: 8755-1039
DOI: 10.1002/dc.20894

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The treatment of recurrent/refractory ch

The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation

✍ Clive S. Zent; Betsy R. LaPlant; Patrick B. Johnston; Timothy G. Call; Thomas M. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

Combination therapy with fludarabine and

Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma : A phase 2 trial of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; Elizabeth R. Vazquez; David R. Spigel; Eric Raefsky; James D 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 2 views

## Abstract ## BACKGROUND The purpose of the current study was to evaluate the efficacy and toxicity of the combination of fludarabine and rituximab, followed by alemtuzumab, as first‐line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ## METHO

Ala228 variant of trail receptor 1 affec

Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer

✍ Stephan Wolf; Daniel Mertens; Armin Pscherer; Petra Schroeter; Dirk Winkler; Her 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 152 KB

## Abstract Allelic loss of chromosome 8p21–22 is a frequent event in various human cancers including mantle cell lymphoma (MCL), prostate cancer, head and neck squamous cell carcinoma (HNSCC) and bladder cancer. The __tumor necrosis factor‐related apoptosis inducing ligand__ (TRAIL) receptors, inc